ArticleCureus2025
Identifying Patients With Asymptomatic Hyperparathyroidism by Serum Calcium and Vitamin D Screening in West Bengal, India.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPrimary hyperparathyroidism (PHPT) is the leading cause of hypercalcemia, with solitary parathyroid adenoma responsible for most cases. Many patients with hyperparathyroidism remain asymptomatic, but early detection and parathyroidectomy can prevent complications such as nephrolithiasis, pancreatitis, and bone and kidney disorders. This study emphasizes the importance of screening for asymptomatic hyperparathyroidism to enable timely intervention.
methodsSerum calcium and Vitamin D3 levels were screened in 6000 outpatients between March 2021 and September 2022. Patients with known hyperparathyroidism, conditions altering calcium metabolism, or those on calcium/Vitamin D supplements were excluded. Vitamin D deficiency was corrected in normocalcemic patients, and follow-up calcium levels were measured. Hypercalcaemic cases underwent additional phosphate and intact parathormone (iPTH) testing. Hyperparathyroidism was confirmed using standard diagnostic criteria, followed by gland localisation and surgery.
resultsAmong 6000 patients screened, 85.2% (5112) had normocalcemia with Vitamin D deficiency. Hypercalcemia was initially observed in three patients, with two additional cases identified post-Vitamin D correction. Of the five hypercalcaemic patients, three were confirmed to have high iPTH levels and low phosphate, leading to surgical intervention. Asymptomatic hyperparathyroidism prevalence was 0.05% (3/6000), constituting 15.8% of all PHPT cases encountered during the study period.
conclusionWhile global asymptomatic hyperparathyroidism prevalence is approximately 1%, this study observed a lower incidence (0.05%) in a West Bengal population. Despite this, early screening and intervention are vital to prevent long-term complications and reduce healthcare burdens.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.